• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Longeveron To Present At Emerging Growth Virtual Conference Dec 5

    GLOBENEWSWIRE

    Longeveron® Announces Q3 2024 Financial Results & Business Update

    GLOBENEWSWIRE

    Longeveron® Appoints Devin as Chief Technology Officer & SVP of CMC

    GLOBENEWSWIRE

    Longeveron® to Report Q3 2024 Results on Nov 12

    GLOBENEWSWIRE

    Longeveron Presents Lomecel-B™ Data for Alzheimer’s at CTAD24

    GLOBENEWSWIRE

    Longeveron® Presents Lomecel-B™ Data in HLHS at CHSS Meeting

    GLOBENEWSWIRE

    Longeveron Lomecel-B Data In Alzheimer`s Selected For CTAD24

    GLOBENEWSWIRE

    Longeveron Lomecel-B Data Selected For CHSS 51st Annual Meeting

    GLOBENEWSWIRE

    Longeveron To Present At UBS Virtual Organ Restoration Day

    GLOBENEWSWIRE

    Longeveron® Joins 3rd Annual ROTH Healthcare Conference

    GLOBENEWSWIRE

    Longeveron To Attend Cell & Gene Meeting On The Mesa

    GLOBENEWSWIRE

    Longeveron Announces Positive FDA Meeting for Lomecel-B in HLHS

    GLOBENEWSWIRE

    Longeveron to Present at H.C. Wainwright Annual Global Investment Conference

    GLOBENEWSWIRE

    Longeveron To Present At H.C. Wainwright Global Investment Conference

    GLOBENEWSWIRE

    Longeveron Announces Q2 2024 Financial Results And Business Update

    GLOBENEWSWIRE

    Longeveron To Report Q2 2024 Results On August 14

    GLOBENEWSWIRE

    Longeveron Shares CLEAR MIND Phase 2a Trial Data On Lomecel-B For Alzheimer`s

    GLOBENEWSWIRE

    Longeveron Closes $9.0M Registered Direct Offering At Market Price

    GLOBENEWSWIRE

    Longeveron Announces $9.0 Million At-Market Offering

    GLOBENEWSWIRE

    Longeveron`s Lomecel-B Gets FDA Fast Track For Mild Alzheimer`s

    GLOBENEWSWIRE

    FDA Grants Longeveron`s Lomecel-B RMAT Status For Mild Alzheimer`s

    GLOBENEWSWIRE

    Neha Motwani Elected to Longeveron® Board of Directors

    GLOBENEWSWIRE

    Gene Therapy Pioneer Roger Hajjar, MD, Elected to Longeveron® Board of Directors

    GLOBENEWSWIRE

    Longeveron Raises $4.4 Million in Gross Proceeds from Warrant Transaction

    GLOBENEWSWIRE

    Longeveron Announces Exercise Of Warrants For $4.4 Million Gross Proceeds

    GLOBENEWSWIRE

    Longeveron To Present At Virtual Life Sciences Investor Forum On June 20, 2024

    GLOBENEWSWIRE

    Longeveron® Announces Completion of Meeting forOn-going Pha2b Trial Lomecel-B™

    GLOBENEWSWIRE

    Longeveron to Present at the Emerging Growth Virtual Conference on June 12, 2024

    GLOBENEWSWIRE

    Longeveron Announces CDMO Business, First Contract

    GLOBENEWSWIRE

    Longeveron® to Attend BIO International Convention 2024

    GLOBENEWSWIRE

    Longeveron Announces Q1 2024 Results, Business Update

    GLOBENEWSWIRE

    Longeveron Announces Board of Directors Planned Transitions

    GLOBENEWSWIRE

    Longeveron Q1 2024 Results, Conference Call On May 14

    GLOBENEWSWIRE

    Longeveron to Present at the Planet MicroCap Showcase

    GLOBENEWSWIRE

    Longeveron Raises $11.4M From Warrant Exercise, Public Offering

    GLOBENEWSWIRE

    Longeveron Announces $6.2M from Warrant Exercises

    GLOBENEWSWIRE

    Longeveron`s Alzheimer`s Data At AAIC Featured Session

    GLOBENEWSWIRE

    Longeveron Announces Closing of $5.2 Million Public Offering

    GLOBENEWSWIRE

    Longeveron Issues Letter to Shareholders

    GLOBENEWSWIRE

    Longeveron Announces Pricing of $5.25 Million Public Offering

    GLOBENEWSWIRE

    Longeveron Announces 1-for-10 Reverse Stock Split

    GLOBENEWSWIRE

    With cash runways ending, Nicox and Longeveron plan layoffs

    FIERCE BIOTECH

    Longeveron Reports Year-End 2023 Results and Provides Corporate Update

    GLOBENEWSWIRE

    Longeveron to Report Year-End 2023 Results

    GLOBENEWSWIRE

    Longeveron Receives Notice of United States Patent Allowance

    GLOBENEWSWIRE

    Longeveron Announces Closing of $2.36 Million Registered Direct Offering

    GLOBENEWSWIRE

    Longeveron Announces $2.36 Million Registered Direct Offering

    GLOBENEWSWIRE

    UPDATE -- Longeveron Announces $2.36 Million Registered Direct Offering

    GLOBENEWSWIRE

    Longeveron Announces Results from the CLEAR MIND Phase 2a Trial of Lomecel-B

    GLOBENEWSWIRE

    Long-term Survival Data from Longeveron™s ELPIS 1 Trial Presented

    GLOBENEWSWIRE

    Longeveron Reports Third Quarter 2023 Results and Provides Corporate Update

    GLOBENEWSWIRE

    Longeveron to Report Third Quarter 2023 Results

    GLOBENEWSWIRE

    Longeveron Featured in Syndicated Broadcast Highlighting Results from CLEAR MIND

    GLOBENEWSWIRE

    Longeveron Announces Closing of $4 Million Registered Direct Offering

    GLOBENEWSWIRE

    Longeveron Announces $4 Million Registered Direct Offering

    GLOBENEWSWIRE

    Longeveron touts PhIIa Alzheimer`s data, but drug`s future remains murky

    ENDPTS

    Longeveron Issues Letter to Stockholders

    GLOBENEWSWIRE

    Survival Data from Longeveron`s ELPIS 1 Trial Accepted for Presentation

    GLOBENEWSWIRE

    Longeveron to Present at the 25th Annual H.C. Wainwright Global Conference

    GLOBENEWSWIRE

    Longeveron to Participate in the 149th Annual National Investment Conference

    GLOBENEWSWIRE

    Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.